<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "DOXOrubicin, pegylated liposomal inj VIAL>
<dose><value>20</value>
<value>40</value>
<value>30</value>
</dose><route><value>IV</value>
</route><form><value>inj VIAL</value>
</form><drug><value>DOXOrubicin, pegylated liposomal inj VIAL</value>
</drug><strength><value>2 mg/mL</value>
</strength><frequency><value>ONCE</value>
</frequency><instruction><value>Administer dose diluted in 250 mL D5W over 30 minutes. (Administer initial dose at a rate no greater than 1 mg/minute.)</value>
<value>Administer dose diluted in 250 mL D5W over 30 minutes. Doses greater than 90 mg to be diluted in 500 mL D5W and administered over 60 minutes. (Administer initial dose at a rate no greater than 1 mg/minute.)</value>
<value>Administer dose diluted in 250 mL D5W over 60 minutes. Doses greater than or equal to 90 mg to be diluted in 500 mL D5W. (Administer initial dose at a rate no greater than 1 mg/minute.)</value>
<value>Administer dose diluted in 250 mL D5W over 60 minutes. (Administer initial dose at a rate no greater than 1 mg/minute to decrease risk of infusion reaction.)</value>
</instruction><volume><value>10 mL</value>
</volume><units><value>mg/m2</value>
</units><additionalnotes><value>Kaposi&amp;apos;s Sarcoma. MAX Lifetime IV DOXOrubicin, liposomal Dose not established, but is suggested to follow recommendations for regular DOXOrubicin formulation: a) No risk factors: 550 mg/m2. b) Concurrent radiation therapy; previous or concurrent use of cyclophosphamide, anthracyclines or other cardiotoxic drugs: 450 mg/m2.</value>
<value>Primary Peritoneal Cancer. MAX Lifetime IV DOXOrubicin, liposomal Dose not established, but is suggested to follow recommendations for regular DOXOrubicin formulation: a) No risk factors: 550 mg/m2. b) Concurrent radiation therapy; previous or concurrent use of cyclophosphamide, anthracyclines or other cardiotoxic drugs: 450 mg/m2.</value>
<value>Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma. MAX Lifetime IV DOXOrubicin, liposomal Dose not established, but is suggested to follow recommendations for regular DOXOrubicin formulation: a) No risk factors: 550 mg/m2. b) Concurrent radiation therapy; previous or concurrent use of cyclophosphamide, anthracyclines or other cardiotoxic drugs: 450 mg/m2.</value>
<value>Ovarian cancer. MAX Lifetime IV DOXOrubicin, liposomal Dose not established, but is suggested to follow recommendations for regular DOXOrubicin formulation: a) No risk factors: 550 mg/m2. b) Concurrent radiation therapy; previous or concurrent use of cyclophosphamide, anthracyclines or other cardiotoxic drugs: 450 mg/m2.</value>
</additionalnotes><population><value>ADULT</value>
</population><indicationprn><value></value>
</indicationprn><backgroundinformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3381</value>
</backgroundinformation><prninformation><value></value>
</prninformation><ahsformularystatus><value>Formulary.</value>
</ahsformularystatus><ahfsname><value>Antineoplastic Agents</value>
</ahfsname><highalert><value>YES</value>
</highalert><maximumprndose><value>YES</value>
</maximumprndose></drug>